People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tolerion, Inc. | — | Biotechnology | Series B | $43.0M | $793.8M | 2017 |
| EXSULIN Corp | — | Biotechnology | Pre-Seed | $1.0M | $8.5M | 2009 |
Alexander Fleming at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alexander Fleming on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Scott Jones | 1 | 11 |
| John Donovan | 1 | 8 |
| Paul Manning | 1 | 6 |
| Sean Stalfort | 1 | 5 |
| Lawrence Steinman | 1 | 4 |
| James Stutz | 1 | 2 |
| Stephen Zachary | 1 | 2 |
| Lisa Jansa | 1 | 1 |
| Scott Geyer | 1 | 1 |
| Graeme Curie | 1 | 1 |
| Randolph Johnson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.